Drugs / CHT105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07517536 | Apr 2026 → Jan 2028 expected | lupus nephritis, systemic lupus erythematosus | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Enrolling by invitation | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHT105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07517536 ↗ |
| Action | Deplete | “This engineered T-cell product effectively recognizes and eliminates immune cells expressing CD19 and/or CD70 antigens” NCT07517536 ↗ |
| Modality | Cell therapy | “allogeneic chimeric antigen receptor T (CAR-T) cell product” NCT07517536 ↗ |
| Route | Intravenous | “participants will receive a single intravenous infusion of CHT105 on Day 0 (D0)” NCT07517536 ↗ |